Core Points - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology, which broadens the scope of immunogenic compositions used in the vaccine [1][2] - The patent covers methods of immunizing patients against breast cancer using an immunogenic composition containing the human α-lactalbumin protein, which is expressed in certain breast cancers [2] - The CEO of Anixa highlighted that this patent enhances the company's intellectual property portfolio, which includes multiple issued and pending patents in the U.S. and internationally [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [3] - The company's vaccine portfolio includes vaccines for breast and ovarian cancer, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - Anixa's business model involves partnerships with renowned research institutions, allowing the company to explore emerging technologies for further development and commercialization [3]